FPR2 is a therapeutic target in lung cancer
FPR2 is a therapeutic target in lung cancer
批准号:
nhmrc : GNT1142013
负责人:
A/Pr Daniel Steinfort
金额:
$89.8万
依托单位:
依托单位国家:
澳大利亚
项目类别:
Project Grants
财政年份:
2018
资助国家:
澳大利亚
项目状态:
已结题
起止时间:
2018-01-01 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Lung cancer remains the biggest cause of cancer related deaths and chronic smoking is the major risk factor. We have recently demonstrated that a protein termed SAA contributes to damaging inflammation in chronic smokers that develop emphysema through activation of a receptor called FPR2. We will determine whether naturally derived products termed pro-resolving mediators that target this same FPR2 receptor will prove to be a novel and effective treatment for lung cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
FPR2 is a therapeutic target in lung cancer
-
批准号:nhmrc : 1142013
-
项目类别:Project Grants
-
资助金额:$60.72万
-
财政年份:2018
-
负责人:A/Pr Daniel Steinfort
-
依托单位:
Use of Molecular Tumour markers to improve diagnostic performance of bronchoscopy in assessment of pulmonary nodules and early diagnosis of lung cancer
-
批准号:nhmrc : GNT1121880
-
项目类别:Early Career Fellowships
-
资助金额:$30.3万
-
财政年份:2017
-
负责人:A/Pr Daniel Steinfort
-
依托单位:
Targeting oxidant-dependent pathways to improve stroke outcomes in COPD
-
批准号:nhmrc : 1120522
-
项目类别:Project Grants
-
资助金额:$73.05万
-
财政年份:2017
-
负责人:A/Pr Daniel Steinfort
-
依托单位:
Targeting oxidant-dependent pathways to improve stroke outcomes in COPD
-
批准号:nhmrc : GNT1120522
-
项目类别:Project Grants
-
资助金额:$106.96万
-
财政年份:2017
-
负责人:A/Pr Daniel Steinfort
-
依托单位:
Use of Molecular Tumour markers to improve diagnostic performance of bronchoscopy in assessment of pulmonary nodules and early diagnosis of lung cancer
-
批准号:nhmrc : 1121880
-
项目类别:Early Career Fellowships
-
资助金额:$20.6万
-
财政年份:2017
-
负责人:A/Pr Daniel Steinfort
-
依托单位:
Use of advanced bronchoscopic techniques in the diagnosis and staging of suspected primary lung cancer.
-
批准号:nhmrc : 520672
-
项目类别:NHMRC Postgraduate Scholarships
-
资助金额:$7.92万
-
财政年份:2008
-
负责人:A/Pr Daniel Steinfort
-
依托单位:
国内基金
海外基金
芍药苷靶向α-烯醇化酶治疗实验性自身免疫性脑脊髓炎的机制研究
-
批准号:82371809
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:聂红
-
依托单位:
新型小分子蛋白—人肝细胞生长因子三环域(hHGFK1)抑制破骨细胞及治疗小鼠骨质疏松的疗效评估与机制研究
-
批准号:82370885
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:姚晨
-
依托单位:
HER2特异性双抗原表位识别诊疗一体化探针研制与临床前诊疗效能研究
-
批准号:82372014
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:魏伟军
-
依托单位: